Side effects and antibody titer transition of the BNT162b2 messenger ribonucleic acid coronavirus disease 2019 vaccine in Japan

Review Pharmacology & Pharmacy

Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273

Shyh Poh Teo

Summary: The FDA recently authorized two mRNA vaccines for COVID-19 prevention, highlighting their high efficacy and providing recommendations for future development. The article also discusses safety data, study results, and logistical considerations for mass vaccination programs.

JOURNAL OF PHARMACY PRACTICE (2022)

添加到收藏夹

Article Medicine, General & Internal

Allergic reactions to COVID-19 vaccines: evidence and practice-oriented approach

L. Klimek et al.

Summary: Vaccines have been approved for mass vaccination programs, but allergic reactions including anaphylaxis remain major concerns. The incidence of anaphylaxis with COVID-19 mRNA vaccines is higher compared to previous vaccines. The focus is on reviewing the components of COVID-19 mRNA vaccines and addressing the clinical presentation, treatment, and potential allergic reactions.

INTERNIST (2021)

添加到收藏夹

Article Medicine, General & Internal

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Noa Dagan et al.

Summary: A study conducted in Israel on nearly 600,000 individuals showed that the BNT162b2 mRNA vaccine was effective in reducing the risk of infection, hospitalization, and severe Covid-19. The effectiveness in preventing death was 72% during the period from day 14 through day 20 after the first dose, and hospitalization was reduced by 87% for the period 7 or more days after the second dose, similar to results from a randomized trial.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Infectious Diseases

Dynamic changes and prevalence of SARS-CoV-2 IgG/IgM antibodies: Analysis of multiple factors

Chunhua Luo et al.

Summary: The study investigated the dynamic characteristics and prevalence of SARS-CoV-2 antibodies, showing that antibody levels peaked within 30 days of symptom onset and then declined continuously. An IgG level of 16.33 +/- 3.15 AU/mL may serve as a threshold value for alerting potential undetectability within the next 30-60 days.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Virology

Back to normal; serological testing for COVID-19 diagnosis unveils missed infections

Tomoya Tsuchida et al.

Summary: Serological testing can help identify COVID-19 infections missed by NAAT, providing important insights for diagnosis and treatment.

JOURNAL OF MEDICAL VIROLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study

Eleftheria Vasileiou et al.

Summary: The study in Scotland found that the first doses of the BNT162b2 mRNA and ChAdOx1 vaccines were associated with substantial reductions in the risk of COVID-19 hospital admission, with vaccine effectiveness ranging from 88% to 91% at 28-34 days post-vaccination.

LANCET (2021)

添加到收藏夹

Article Immunology

Prevalence of SARS-CoV-2-Specific Antibodies, Japan, June 2020

Takashi Yoshiyama et al.

Summary: The study used 2 commercially available antibody tests to estimate seroprevalence of SARS-CoV-2 infection in Japan in June 2020, and found 8 positive samples out of 7,950. Using 2 reliable antibody tests in low prevalence settings is an effective method for estimating seroprevalence.

EMERGING INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Medicine, General & Internal